 

 

 

I.

I

PATIENT HISTORYA, .
CHIEF COMPLAINT/ PﬁE—OP/ posrop DIAGNOSIS: Endomelnal cancer.

DATE: Not rovided. _ _ .
‘PkﬁﬂgCEDUFIE: Tglal abdominal hysterectomy. bilateral solpmgo-oophorecmmy, omentestomy, hemra l’epﬂll'.
SPECIFIC CLINICAL QUESTION; Not provided.

OUTSIDE TISSUE DIAGNOSIS: No. UUID:76630416—13EC-4ASB-5655-F7DCCC9C8E8D

PRIOR MALIGNANCY: No. i. TCGA-BG-ABW-eiA-PR Redacted
C“EM°"“5%'2§'§£LZE"APY=“°' ‘ IIIIIIIIIIIIIIIIIIIIIIIIIIllIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII
33552.1”. ' ' IIIIIIIIIIllIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII
Evaluation 0} endometrial tumor .. limit... by mm changes. III III! II IIIIIIIIIIIIIIIIIIIIIIIII I II I IIIII I IIIII II IIIII I IIII III
Immunohlstoehemlcal stains were performed for evaluation ot this tumor and the presence of lymphovescular space

Invasion (please see microscopic description Ior complete report). / CA - d ’3

Companion pelvic wash _ls negative for tumor W Wth I N05 fjgd/j
Pathologic stage: T‘I aNoMx, ﬁao algcurrent classiﬁcation). 55% ; W (55% /
MICROSCOPIC: , - -" I. 57
Antibody/Antigen -' Result '//'
PIG Patchy positive .

P53 Negative

P63 Negative

CD31 Positive in endothelial. lymphatic and vascular channels .

D2 40 Positive in endothelial, lymphatic and vascular channels .

CD34 Positive in endothel iel , lymphatic and vascular channels .

Utilizing formalin—fixed (8-96 hour range), paraffin embedded tissue, imunohistology is
performed with the following selected antibodies and designated antibody cloneis). directed
against the following antigenic target(s), with adequate positive and negative internal and
external controls. Antibodies are optimized appropriate for fixation times.

ANTIBODY CLONE TARGET»ANTIGEN VENDOR
p16 16P04IJC2i HPV surrogate

P53 Do—7 Serous Carcinoma

p63 4A4 + Y4A3 Myoepithelial cells

CD 31 JC70 endothelium

02-40 D2-40 Lymphatic Endotheliurn

CD 34 QBEmd/lo endothelium

Microscopic examination substantiates the above diagnosis.

The l‘ollowlng statement applies to all lmmunohistochemletry, lnsitu hybridization (ISH a FISH), molecular anatomic pathology, and
lmrnunolluorescence teatlng:

The testing was developed and no parlour-lance characterilrtica determined by the I

required by the CLIA '88 regulations. The testing has not been cleared or approved for the epociﬂc use by the U3. race and Drug '-
Admlnletratlon, but the FDA has determined such approval I: not necessary for clinical use.

see

This laboratory is certified under the Clinical Laboratorytmprovoment Amendments at 1968 ('CLIA") as qualified to per-term high-

comploxity clinical testing. Pursuant to the requirements a! CLIA, Asn'o used In this laboratory have been established and veriﬁed for
accuracy and precision. Additional Information about this type ol test is available upon request.

CASE SYNOPSIS:
SYNOPTIC ~ PRIMARY UTERINE EMQOMETRIAL TUMOR31HYSTEREQTOMY SPECIMENS
TUMOR TYPE: Enuometroid adenocargioome. NOSE

HISTOLOGIG GRADE (epithelial neoplEsmTIéoﬁthnodimhitectuml and nuclear]:
Well differentiated (FIGO 1),)

ARCHITECTURAL GRADE: Well differentiated-d!"
NUCLEAR GRADE: Grade 2
TUMOR SIZE: Maximum dimension: 2.0 cm

PERCENT OF ENDOMETRIAL SURFACE INVOLVEMENT:
Anterior endomyometrium: 10 %, Posterior endomyometrium: 30 %

DEPTH OF INVASION“: Less than 1/2 thickness of myometriurn
ANGIOLYMPHATIC INVASION: ’ No

OTHER: (epithelial, smooth muscle, others). Leiomyoma
LYMPH MODES POSITIVE: Number of lymph nodes positive: 0

LYMPI-l NODES EXAMINED: Total number of lymph nodes examined: 10

T STAGE, PATHOLOGIC: pTib

N STAGE, PATHOLOGIC: pNO

M STAGE, PATHOLOGIC: pMX

FIGO STAGE: IB

Initials

 

